SCHEMBL393194

SCHEMBL393194

CC(C)(C)N(CC(=O)OCc1ccccc1)C(=O)OCOC(=O)c1cccnc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.60
LMNA P02545 3/20 0.60
KMT2A Q03164 3/20 0.60
HDAC1 Q13547 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393109 0.89 KMT2A (0.44) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL393373 0.86 LMNA (0.49) TDP1LMNAKMT2AL3MBTL1ALDH1A1
SCHEMBL395726 0.85 KMT2A (0.48) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL394173 0.83 MAPT (0.47) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL392819 0.83 MAPT (0.49) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL393493 0.82 MAPT (0.45) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL392216 0.82 TDP1 (0.41) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL395276 0.82 MAPT (0.45) TDP1LMNAKMT2AL3MBTL1RAB9A
SCHEMBL395232 0.81 MAPT (0.44) TDP1LMNAKMT2ARAB9ASLC6A2
SCHEMBL390695 0.80 MAPT (0.44) TDP1LMNAKMT2AL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 TDP1 4661/4885LMNA 2954/4885KMT2A 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.